Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6449
+0.00380.59%
Pre-market: 0.66000.0151+2.34%05:57 EDT
Volume:9.49M
Turnover:6.07M
Market Cap:156.71M
PE:-0.86
High:0.6586
Open:0.6500
Low:0.6191
Close:0.6411
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.86
T/O Rate:4.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-15.08
PE(LYR):-0.36

Loading ...

Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright

Reuters
·
May 14

Outlook Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 11

Outlook Therapeutics closes USD 5 million registered direct offering at USD 0.31/share

Reuters
·
Apr 24

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Dow Jones
·
Apr 24

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

TIPRANKS
·
Apr 22

Outlook Therapeutics prices 16,129,033-share registered direct offering at USD 0.31

Reuters
·
Apr 22

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Apr 22

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

TIPRANKS
·
Apr 22

BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)

Reuters
·
Apr 21

Outlook Therapeutics Inc - Expects FDA Feedback in May 2026

THOMSON REUTERS
·
Apr 21

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Benzinga_recent_news
·
Apr 08

Outlook Therapeutics submits formal dispute resolution request to FDA

TIPRANKS
·
Apr 07

BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision

Reuters
·
Apr 07

BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA

Reuters
·
Apr 07

Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds

Reuters
·
Mar 26

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Dow Jones
·
Mar 26

Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced

MT Newswires Live
·
Mar 25

Outlook Therapeutics prices USD 5 million public offering at USD 0.25 per share with warrants

Reuters
·
Mar 24

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

THOMSON REUTERS
·
Mar 24

BRIEF-Outlook Therapeutics Announces Proposed Public Offering

Reuters
·
Mar 24